Signals, Powered By EquityPandit
Sun Pharmaceuticals Industries has received approval from USFDA, for its psoriasis drug Ilumya.
Ilumya is generically known as tildrakizumab-asmn and comes under specialty drugs – medications that treats complex or rare diseases such as cancer, autoimmune disorders, skin conditions among others. It is used for the treatment of the most common plaque psoriasis – a chronic immune disease that appears on the skin.
Abhay Gandhi, President and CEO, North America, Sun Pharma stated, “With the approval of ILUMYA and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis.”
